Glucose Metabolism and Its Controlling Mechanisms in Entamoeba histolytica

Pineda, Erika; Encalada, Rusely; Vázquez, Citlali; González, Zabdi; Moreno‐Sánchez, Rafael; Saavedra, Emma

doi:10.1007/978-4-431-55200-0_20

Cited by 2 publications

(3 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a very crucial enzyme as it exhibits activities of both, alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) ( Espinosa et al., 2016 ). The parasite lacks Krebs cycle and relies on fermentation of glucose to ethanol for energy generation ( Pineda et al., 2015 ). The two final steps of the glycolytic pathway are catalysed by this enzyme - the conversion of acetyl-CoA to acetaldehyde and the reduction of acetaldehyde to ethanol.…”

Section: Metabolic Drug Targetsmentioning

confidence: 99%

“…One of the important enzymes, phosphosphofructokinase (PFK) is coded by the genome of this parasite. The amoebic PFK is different from its human counterpart as it uses pyrophosphate as its cofactor unlike the human PFK which is ATP-dependent ( Pineda et al., 2015 ). Targeting the sole energy generating pathway of this parasite seems to be a very efficient strategy to kill the parasite in the host system, especially when the enzyme involved has a different mode of operation for the same biochemical reaction.…”

Section: Metabolic Drug Targetsmentioning

confidence: 99%

See 1 more Smart Citation

Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis

Shrivastav

Malik

Somlata

2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Amebiasis is a neglected tropical disease which is caused by the protozoan parasite Entamoeba histolytica. This disease is one of the leading causes of diarrhea globally, affecting largely impoverished residents in developing countries. Amebiasis also remains one of the top causes of gastrointestinal diseases in returning international travellers. Despite having many side effects, metronidazole remains the drug of choice as an amebicidal tissue-active agent. However, emergence of metronidazole resistance in pathogens having similar anaerobic metabolism and also in laboratory strains of E. histolytica has necessitated the identification and development of new drug targets and therapeutic strategies against the parasite. Recent research in the field of amebiasis has led to a better understanding of the parasite’s metabolic and cellular pathways and hence has been useful in identifying new drug targets. On the other hand, new molecules effective against amebiasis have been mined by modifying available compounds, thereby increasing their potency and efficacy and also by repurposing existing approved drugs. This review aims at compiling and examining up to date information on promising drug targets and drug molecules for the treatment of amebiasis.

show abstract

Section: Metabolic Drug Targetsmentioning

confidence: 99%

Section: Metabolic Drug Targetsmentioning

confidence: 99%

Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis

Shrivastav

Malik

Somlata

2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…It is the main metabolic pathway in E. histolytica because this amoeba lacks the genes that encode the enzymes of the Krebs cycle and oxidative phosphorylation; consequently, it relies on substratelevel phosphorylation to provide high-energy compounds. 13,14 This protozoan parasite uses an unusual PPi-dependent glycolytic pathway in which ATP-dependent phosphofructokinase is replaced by PPi-dependent phosphofructokinase (PPi-PFK), and pyruvate kinase is replaced by a PPi-dependent pyruvate phosphate dikinase (PPi-PPDK). 13,15 A strategy to develop new drugs to kill the parasite has been proposed that exploits differences between parasite and human glycolytic pathway enzymes.…”

Section: Introductionmentioning

confidence: 99%

In Vitro Testing of Potential Entamoeba histolytica Pyruvate Phosphate Dikinase Inhibitors

Saidin

Othman

Noordin

2017

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Adverse effects and resistance to metronidazole have motivated the search for new antiamoebic agents against . Control of amoeba growth may be achieved by inhibiting the function of the glycolytic enzyme and pyruvate phosphate dikinase (PPDK). In this study, we screened 10 compounds using an in vitro PPDK enzyme assay. These compounds were selected from a virtual screening of compounds in the National Cancer Institute database. The antiamoebic activity of the selected compounds was also evaluated by determining minimal inhibitory concentrations (MICs) and IC values using the nitro-blue tetrazolium reduction assay. Seven of the 10 compounds showed inhibitory activities against the adenosine triphosphate (ATP)/inorganic phosphate binding site of the ATP-grasp domain. Two compounds, NSC349156 (pancratistatin) and NSC228137 (7-ethoxy-4-[4-methylphenyl] sulfonyl-3-oxido-2, 1, 3-benzoxadiazol-3-ium), exhibited inhibitory effects on the growth of trophozoites with MIC values of 25 and 50 μM, and IC values of 14 and 20.7 μM, respectively.

show abstract

Glucose Metabolism and Its Controlling Mechanisms in Entamoeba histolytica

Cited by 2 publications

References 78 publications

Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis

Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis

In Vitro Testing of Potential Entamoeba histolytica Pyruvate Phosphate Dikinase Inhibitors

Contact Info

Product

Resources

About